Literature DB >> 33337959

Secreted frizzled protein 3 is a novel cardioprotective mechanism unique to the clinically relevant fourth window of ischemic preconditioning.

Dorothy E Vatner1, Jie Zhang1, Xin Zhao1, Lin Yan1, Raymond Kudej1, Stephen F Vatner1.   

Abstract

Most studies on ischemic preconditioning (IPC) use one or two ischemic stimuli before examining cardioprotection. To better simulate the clinical situation, we examined, in pigs, the effects of six episodes of 10 min coronary artery occlusion (CAO) 12 h apart, followed by 60 min CAO. We named this model the fourth window of IPC. To determine the novel mechanisms mediating cardioprotection in the fourth window, gene analysis was examined in fourth window IPC cardiac tissue 60 min after the last episode of 10 min CAO. Secreted frizzled-related protein 3 (sFRP3) was the most significantly upregulated gene that was unique to the fourth window, that is, not found in the first, second, or third window IPC. To study the effects of sFRP3 on cardioprotection, sFRP3 was injected in the hearts of wild-type (WT) mice. In the [CAO/coronary artery reperfusion (CAR)] model (30 min CAO followed by 24 h CAR), infarct size was less, P < 0.01, after sFRP3 injection (14% ± 1.7%) compared with vehicle injection (48% ± 1.6%). sFRP3 injection also protected the development of heart failure following permanent CAO for 2 wk. Left ventricular ejection fraction was significantly improved, P < 0.05, at 2 wk after CAO with sFRP3 (53% ± 5%) compared with vehicle (36% ± 2%) and was accompanied by significant, P < 0.01, reductions in myocardial fibrosis (53% ± 4%), myocyte size (17% ± 3%), apoptosis (100%), and mortality (56%). Thus, sFRP3, unique to the clinically relevant fourth window IPC model, is a novel mechanism mediating ischemic cardioprotection.NEW & NOTEWORTHY 1) This investigation identifies the novel fourth window of ischemic preconditioning. 2) sFRP3 was identified as the most significantly upregulated gene in the fourth window and was shown to induce cardioprotection when administered to the hearts of wild-type mice.

Entities:  

Keywords:  heart failure; ischemic heart; ischemic preconditioning; sFRP3

Mesh:

Substances:

Year:  2020        PMID: 33337959      PMCID: PMC8082796          DOI: 10.1152/ajpheart.00849.2020

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  33 in total

1.  Second window of preconditioning normalizes palmitate use for oxidation and improves function during low-flow ischaemia.

Authors:  Raymond K Kudej; Mathew Fasano; Xin Zhao; Gary D Lopaschuk; Susan K Fischer; Dorothy E Vatner; Stephen F Vatner; E Douglas Lewandowski
Journal:  Cardiovasc Res       Date:  2011-08-11       Impact factor: 10.787

2.  Activation of the cardiac proteasome during pressure overload promotes ventricular hypertrophy.

Authors:  Christophe Depre; Qian Wang; Lin Yan; Nadia Hedhli; Pallavi Peter; Li Chen; Chull Hong; Luc Hittinger; Bijan Ghaleh; Junichi Sadoshima; Dorothy E Vatner; Stephen F Vatner; Kiran Madura
Journal:  Circulation       Date:  2006-10-16       Impact factor: 29.690

3.  H11 kinase prevents myocardial infarction by preemptive preconditioning of the heart.

Authors:  Christophe Depre; Li Wang; Xiangzhen Sui; Hongyu Qiu; Chull Hong; Nadia Hedhli; Audrey Ginion; Amy Shah; Michel Pelat; Luc Bertrand; Thomas Wagner; Vinciane Gaussin; Stephen F Vatner
Journal:  Circ Res       Date:  2005-12-22       Impact factor: 17.367

Review 4.  Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection.

Authors:  Hans Erik Bøtker; Derek Hausenloy; Ioanna Andreadou; Salvatore Antonucci; Kerstin Boengler; Sean M Davidson; Soni Deshwal; Yvan Devaux; Fabio Di Lisa; Moises Di Sante; Panagiotis Efentakis; Saveria Femminò; David García-Dorado; Zoltán Giricz; Borja Ibanez; Efstathios Iliodromitis; Nina Kaludercic; Petra Kleinbongard; Markus Neuhäuser; Michel Ovize; Pasquale Pagliaro; Michael Rahbek-Schmidt; Marisol Ruiz-Meana; Klaus-Dieter Schlüter; Rainer Schulz; Andreas Skyschally; Catherine Wilder; Derek M Yellon; Peter Ferdinandy; Gerd Heusch
Journal:  Basic Res Cardiol       Date:  2018-08-17       Impact factor: 17.165

5.  The cardiokine secreted Frizzled-related protein 3, a modulator of Wnt signalling, in clinical and experimental heart failure.

Authors:  E T Askevold; P Aukrust; S H Nymo; I G Lunde; O J Kaasbøll; S Aakhus; G Florholmen; I K Ohm; M E Strand; H Attramadal; A Fiane; C P Dahl; A V Finsen; L E Vinge; G Christensen; A Yndestad; L Gullestad; R Latini; S Masson; L Tavazzi; T Ueland
Journal:  J Intern Med       Date:  2014-01-09       Impact factor: 8.989

6.  Novel mechanisms for caspase inhibition protecting cardiac function with chronic pressure overload.

Authors:  Misun Park; Stephen F Vatner; Lin Yan; Shumin Gao; Seunghun Yoon; Grace Jung Ah Lee; Lai-Hua Xie; Richard N Kitsis; Dorothy E Vatner
Journal:  Basic Res Cardiol       Date:  2013-01-01       Impact factor: 17.165

7.  Expression of secreted frizzled related proteins 3 and 4 in human ventricular myocardium correlates with apoptosis related gene expression.

Authors:  H Schumann; J Holtz; H R Zerkowski; M Hatzfeld
Journal:  Cardiovasc Res       Date:  2000-02       Impact factor: 10.787

8.  Proteasome activation during cardiac hypertrophy by the chaperone H11 Kinase/Hsp22.

Authors:  Nadia Hedhli; Li Wang; Qian Wang; Eman Rashed; Yimin Tian; Xiangzhen Sui; Kiran Madura; Christophe Depre
Journal:  Cardiovasc Res       Date:  2007-10-30       Impact factor: 10.787

9.  Activation of Mst1 causes dilated cardiomyopathy by stimulating apoptosis without compensatory ventricular myocyte hypertrophy.

Authors:  Shimako Yamamoto; Guiping Yang; Daniela Zablocki; Jing Liu; Chull Hong; Song-Jung Kim; Sandra Soler; Mari Odashima; Jill Thaisz; Ghassan Yehia; Carlos A Molina; Atsuko Yatani; Dorothy E Vatner; Stephen F Vatner; Junichi Sadoshima
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

10.  Guidelines for experimental models of myocardial ischemia and infarction.

Authors:  Merry L Lindsey; Roberto Bolli; John M Canty; Xiao-Jun Du; Nikolaos G Frangogiannis; Stefan Frantz; Robert G Gourdie; Jeffrey W Holmes; Steven P Jones; Robert A Kloner; David J Lefer; Ronglih Liao; Elizabeth Murphy; Peipei Ping; Karin Przyklenk; Fabio A Recchia; Lisa Schwartz Longacre; Crystal M Ripplinger; Jennifer E Van Eyk; Gerd Heusch
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-01-12       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.